Summary
This Phase II trial of atezolizumab with or without radiotherapy for advanced penile squamous cell carcinoma did not meet its primary endpoint of 1-year progression-free survival. However, a subset of patients demonstrated durable responses to atezolizumab monotherapy. The authors identify human papillomavirus infection status and CD8+ T-cell tumour infiltration as potential predictive biomarkers that may enable better patient selection for immunotherapy in this rare malignancy.
Regional applicability
As a rare cancer treatment trial published in a major oncology journal, findings would be relevant to UK oncology centres and the NHS Cancer Drugs Fund consideration process. UK applicability depends on regulatory approval status and comparative efficacy data versus standard treatment pathways in the National Health Service.
Key measures
1-year progression-free survival; objective response rates; biomarker status (hrHPV positivity, intratumoral CD3+CD8+ T-cell infiltration)
Outcomes reported
The study evaluated 1-year progression-free survival (PFS) as the primary endpoint in patients with advanced squamous cell carcinoma of the penis treated with atezolizumab (an immunotherapy checkpoint inhibitor), with or without radiotherapy. Secondary outcomes included assessment of antitumour response and identification of biomarkers predictive of treatment response.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.